Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options

Presenter: Margaret A. Tempero

Although we are “winning the war against cancer,” pancreatic malignancies are expected to be the most common cause of cancer-related death by 2040. Several systemic therapies, such as oxaliplatin + irinotecan/fluorouracil/leucovorin (FOLFIRINOX) and gemcitabine + nab-paclitaxel, have shown activity in the adjuvant and neoadjuvant settings. The current NCCN Guidelines reflect the most up-to-date, evidence-based data relating to the evaluation and management of pancreatic adenocarcinoma. They were recently updated to recommend germline testing for any patient with pancreatic cancer and molecular analysis of any metastatic pancreatic tumor.

Disclosures: Dr. Tempero has disclosed serving as a scientific advisor for Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, and Seagen, Inc; receiving consulting fees from BioSapien, Debiopharm, Incyte Corporation, Insmed Inc., Ipsen, Karyopharm Therapeutics, and Novartis Pharmaceuticals Corporation; and grant/research support from Celgene Corporation and Halozyme, Inc.

Correspondence: Margaret A. Tempero, MD, UCSF Pancreas Center, University of California, San Francisco, UCSF Mission Bay Campus/Mission Hall, 550 16th Street, 6th Floor, Box 3211, San Francisco, CA 94143. Email: margaret.tempero@ucsf.edu
  • 1.

    Pancreatic Cancer Action Network. The Alarming Rise of Pancreatic Cancer Deaths in the United States: Why We Need to Stem the Tide Today. Accessed August 18, 2017. Available at https://b0279e4bd99455edf432-0e17ed1620a25e0243e5f59c02373f7f.ssl.cf2.rackcdn.com/wp-content/uploads/2013/01/incidence_report_2012_executive_summary.pdf

    • Search Google Scholar
    • Export Citation
  • 2.

    Pancreatic Cancer Action Network. Pancreatic cancer facts 2016. Accessed August 18, 2017. Available at: https://www.pancan.org/wp-content/uploads/2016/02/2016-GAA-PC-Facts.pdf

    • Search Google Scholar
    • Export Citation
  • 3.

    Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:12181249.

  • 4.

    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:18171825.

  • 5.

    Von Hoff D, Ervin T, Arena F, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT) [abstract]. Presented at the ASCO 2013 Gastrointestinal Cancers Symposium, January 24–26, 2013; San Francisco, California. Abstract LBA148.

    • Search Google Scholar
    • Export Citation
  • 6.

    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:16911703.

  • 7.

    Dahan L, Williet N, Le Malicot K, et al. Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial. J Clin Oncol 2021;39:32423250.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317327.

  • 9.

    Kindler HL, Hammel P, Reni M, et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial [abstract]. J Clin Oncol 2019;37(Suppl):Abstract LBA4.

    • Search Google Scholar
    • Export Citation
  • 10.

    Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:10111024.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Tempero MA, Reni M, Riess H, et al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine for surgically resected pancreatic adenocarcinoma [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 4000.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Sohal DPS, Duong M, Ahmad S, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 2021;7:421427.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Tempero MA, Malafa MP, Al-Hawary M, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Pancreatic Adenocarcinoma. Version 1. 2022. Accessed February 28, 2022. Available at NCCN.org

    • Search Google Scholar
    • Export Citation
  • 14.

    O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38:13781388.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Collisson EA, Bailey P, Chang DK, et al. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 2019;16:207220.

  • 16.

    Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal tumors harboring a KRAS G12C mutation [abstract]. Presented at the ASCO 2022 Gastrointestinal Cancers Symposium; January 20–22, 2022; San Francisco, California. Abstract 519.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 490 490 490
PDF Downloads 290 290 290
EPUB Downloads 0 0 0